logo
#

Latest news with #BharatSerumsandVaccines

Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create
Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create

Economic Times

time23-06-2025

  • Business
  • Economic Times

Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create

Stir things up Rollout of the ₹5,000-cr Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme signals a shift in how India approaches the sector's growth. This initiative, expected to begin disbursals by the end of 2025, could attract ₹17,000 cr in additional R&D investment. For an industry that has long been associated with generic manufacturing, this represents a paradigm shift towards innovation-led pharma world is approaching a 'patent cliff', and for Indian firms, it represents an unprecedented opportunity: 24 mega-selling drugs with combined annual sales exceeding $250 bn will lose patent protection by 2030. This means blockbuster medicines like Humira for rheumatoid arthritis, Keytruda for cancer treatment, Stelara for psoriasis, and Symbicort for asthma will soon be open for generic manufacturing. When these patents expire, drug prices fall by at least 50%. For a country where out-of-pocket (OoP) healthcare expenses are high, this holds immense significance alongside its commercial potential. Capturing these opportunities won't be easy. Indian firms will face tough competition from generics and must match the original drug standards. Success will hinge on investment in bioequivalence studies, regulatory compliance and resilient supply chains. Indian pharma companies are eyeing these opportunities. Zydus, Sun Pharma, and Bharat Serums and Vaccines (now part of Mankind Pharma) have invested in establishing world-class R&D centres, focusing on developing new chemical entities. The younger generation of scientists and entrepreneurs, bringing fresh perspectives, is accelerating the transition from a generic-focused industry to one that balances both generic excellence and innovative drug discovery. MNCs are also rethinking their view of the Indian market: Novartis, Novo Nordisk and Eli Lilly have chosen to out-license their brands to Indian firms rather than directly market them here. This trend reflects both the growing capabilities of domestic firms and the unique challenges of serving India's diverse and price-sensitive market. These partnerships benefit all. International companies can maintain a presence in India without the complexities of direct operations, while Indian firms gain access to established brands and molecules, leveraging deep market understanding and extensive distribution networks. However, building these relationships requires investment in compliance systems, quality infrastructure, and continuous capability upgrades to meet the exacting standards of international positives in the sector include: Exemption of 36 life-saving drugs from basic customs duty will benefit companies bringing in innovative medicines. Drugs like AstraZeneca's Selumetinib, Pfizer's Lorlatinib, Novartis' Ribociclib, and GSK's Mepolizumab will now be more affordable. Additionally, six more life-saving medicines have been added to the concessional 5% duty slab, primarily targeting cancer, rare diseases and other chronic conditions. The health budget has risen to over ₹95,000 cr for FY26, up 9.46%. More than a numbers game, it's about building a healthcare ecosystem fit for our vast population. 15,479 Jan Aushadhi Kendras provide generic medicines at prices up to 80% lower than branded equivalents. A heart medicine that once cost ₹500 is available for ₹100, bringing essential treatments within reach of ordinary citizens. Yet, ensuring consistent quality and maintaining reliable supply chains remain a challenge. Extension of PM Ayushman Yojana to people above 70 years creates a virtuous cycle - more people seeking treatment drives demand for medicines, which, in turn, encourages pharma companies to invest in better products and wider distribution. Development of healthcare infra in tier-2 and tier-3 cities is also helping. However, attracting and retaining qualified medical professionals in these locations remains a hurdle, requiring innovative approaches to compensation, career development and quality-of-life considerations. Again, the market for pharma products will, then, be able to expand. A 'nutraceutical revolution' is underway. With the market expected to grow from $4 bn in 2020 to $18 bn by December, nutraceuticals represent a significant growth avenue for companies willing to invest in quality and innovation. The convergence of multiple factors - patent opportunities, GoI support, infrastructure development and changing consumer behaviour - is creating unprecedented opportunities for the sector. Companies that embrace innovation, while maintaining traditional strengths in affordable healthcare delivery, will thrive. The writer is CEO, Mankind Pharma (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Second only to L&T, but controversies may weaken this infra powerhouse's growth story Looking for quick buck in unlisted shares? Better think twice! How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Stock Radar: Supreme Industries stock down by about 30%! Breakout from rounding bottom formation suggests bulls are catching up Two Trades for Today: A large-cap auto major for 6.7% gain, a mid-cap auto stock for almost 7% rise After a gap of 4 years, are HDFC, Axis, Kotak banks ready for re-rating? 5 bank stocks with upside potential of up to 35% For medium- to long-term investors with moderate risk appetite: 6 large-cap stocks with an upside potential of up to 40%

Mankind Pharma shares slide 3% as Q4 profit declines; details here
Mankind Pharma shares slide 3% as Q4 profit declines; details here

Business Standard

time22-05-2025

  • Business
  • Business Standard

Mankind Pharma shares slide 3% as Q4 profit declines; details here

Shares of Mankind Pharma dropped over 3 per cent on Thursday as the company reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25). The Delhi-based pharma major's stock fell as much as 3.22 per cent during the day to ₹2,450 per share, the biggest intraday fall since May 2 this year. The stock pared losses to trade 2.1 per cent lower at ₹2,478 apiece, compared to a 1 per cent decline in Nifty 50 as of 9:32 AM. Shares of the company extended losses to their fourth day and have fallen over 6 per cent from their recent highs of ₹2,610, which it hit earlier this month. The counter has fallen 14 per cent this year, compared to a 3.7 per cent advance in the benchmark Nifty 50. Mankind Pharma has a total market capitalisation of ₹1.01 trillion, according to BSE data. Mankind Pharma Q4FY25 results Mankind Pharma posted a 10 per cent fall in consolidated net profit Q4 FY25 at ₹424.65 crore from ₹476.59 crore in the same period last financial year. The pharma company's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. It added that this growth was partially supported by continued outperformance in the chronic segment, at 1.3 times the Indian pharma market. Mankind Pharma management commentary Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. About Mankind Pharma The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS vitamins /minerals/nutrients and respiratory.

Mankind Pharma shares drop over 2% as Q4 profit declines 10% and margins miss estimates
Mankind Pharma shares drop over 2% as Q4 profit declines 10% and margins miss estimates

Business Upturn

time22-05-2025

  • Business
  • Business Upturn

Mankind Pharma shares drop over 2% as Q4 profit declines 10% and margins miss estimates

By Aditya Bhagchandani Published on May 22, 2025, 09:23 IST Shares of Mankind Pharma slipped 2.15% to ₹2,477.00 in early trade on Wednesday after the company reported weaker-than-expected quarterly earnings. The stock had closed at ₹2,531.40 in the previous session. The Delhi-based pharmaceutical firm posted a 10% year-on-year decline in consolidated net profit for Q4 FY25 at ₹424.65 crore, down from ₹476.59 crore in the same quarter last year. While revenue from operations surged 27% YoY to ₹3,079 crore from ₹2,422 crore, the market was disappointed by margin performance. EBITDA for the quarter stood at ₹686 crore compared to ₹589 crore last year. However, EBITDA margin contracted to 22.3% from 24.3%, falling short of analyst expectations. The company also issued margin guidance for FY26 that was below Street estimates. Vice-Chairman and Managing Director Rajeev Juneja attributed revenue growth to strong traction in chronic therapies, recovery in the consumer segment, and the consolidation of Bharat Serums and Vaccines (BSV). Mankind's domestic market share rose from 4.4% in March 2024 to 4.8% in March 2025, driven by growth in the gynaecology segment. Despite revenue momentum, concerns over profitability and guidance led to negative investor sentiment on Wednesday. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store